Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence
Copyright © 2021 by the American Academy of Pediatrics..
Children with sickle cell disease (SCD) are at risk for neurologic and cognitive complications beginning in early childhood. Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes. In this article, the prevalence, pathophysiology, and available interventions to prevent and treat neurologic and cognitive complications of SCD will be reviewed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
NeoReviews - 22(2021), 8 vom: 22. Aug., Seite e531-e539 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mayer, Sarah L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antisickling Agents |
|---|
| Anmerkungen: |
Date Completed 02.11.2021 Date Revised 09.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1542/neo.22-8-e531 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328856649 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328856649 | ||
| 003 | DE-627 | ||
| 005 | 20231225203838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1542/neo.22-8-e531 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM328856649 | ||
| 035 | |a (NLM)34341160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mayer, Sarah L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2021 | ||
| 500 | |a Date Revised 09.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the American Academy of Pediatrics. | ||
| 520 | |a Children with sickle cell disease (SCD) are at risk for neurologic and cognitive complications beginning in early childhood. Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes. In this article, the prevalence, pathophysiology, and available interventions to prevent and treat neurologic and cognitive complications of SCD will be reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antisickling Agents |2 NLM | |
| 650 | 7 | |a Hydroxyurea |2 NLM | |
| 650 | 7 | |a X6Q56QN5QC |2 NLM | |
| 700 | 1 | |a Fields, Melanie E |e verfasserin |4 aut | |
| 700 | 1 | |a Hulbert, Monica L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NeoReviews |d 2008 |g 22(2021), 8 vom: 22. Aug., Seite e531-e539 |w (DE-627)NLM195600312 |x 1526-9906 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:8 |g day:22 |g month:08 |g pages:e531-e539 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1542/neo.22-8-e531 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 8 |b 22 |c 08 |h e531-e539 | ||